Publication
Article
Pharmacy Times
Author(s):
A recent Euro-pean study examined the contribution of the metabolic syndrome to the risk of developing venous throm-boembolism (VTE). This case?control study was designed to investigate the presence of the metabolic syndrome, defined according to guidelines of the National Cholesterol Education Program, in high-risk patients with objectively confirmed recurrent VTE who had had at least 1 unprovoked event of deep vein thrombosis or pulmonary embolism. A total of 116 VTE patients and 129 controls were enrolled. The prevalence of the metabolic syndrome was statistically significantly higher in VTE patients (40/116; 35%) than in controls (26/129; 20%; P = .012). The adjusted odds ratio of the metabolic syndrome for VTE was 2.2 after adjustment for established thrombosis risk factors, sex, and age. Individuals with the metabolic syndrome (n = 66) had significantly higher levels of high-sensitivity C-reactive protein, fibrinogen, and factor VIII activity, compared with patients without metabolic syndrome.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.